US revenues dependant on approvals: Despite Appotex approval for Abilify there is no major price action. We believe this opportunity should continue in the current year. In FY17E, Abilify revenues would be dependent on competitive landscape as there were 21 filers in this space. The company has 19 pending filings, of which 10 are niche and less competitive products. Torrent expects 5-6 approvals every year. Nexium approval is expected in Dec.15.